Articles related to BLEEDING/BLOOD DISORDERS

The first treatment for light-chain amyloidosis was approved by the FDA in 2021. Daratumumab-based regimens produce profound hematologic and organ responses, providing a new therapeutic foundation. Early detection, correct fibril typing, the challenges of the very advanced patient, and the lack of therapies to remove amyloid deposits are all being researched but remain elusive.

The timing of re-initiation of antithrombotic therapy needs to be individualized based on the severity of the bleed, among other factors. This article reviews the issue and offers tools and guidelines for determining if and when to restart antiplatelet and oral anticoagulant therapy.

Working from the hypothesis that stomach ulcer bleeds in people on long-term low-dose aspirin therapy was secondary to H. pylori infection, this team gave antibiotic treatment to aspirin takers who test positive for the bacteria, and followed them for up to 7 years. Protection started rapidly and persisted, while diminishing somewhat, over the period of observation.

In the US, reports of COVID-related clots have declined. But social media posts in the UK indicate a rise there – and typically what the UK reports is a harbinger of what is coming to the US.

This “Clinician POV” with Joshua Strauss, MD, a hematologist-oncologist with Advanced Care Hematology & Oncology Associates in New Jersey, discusses the available formulations of parenteral iron and their respective risks for hypophosphatemia, patient- and disease-related factors of the condition, administration of the formulations, monitoring, and more.

Blue sclera has an 87% to 89% sensitivity and a 64% to 94% specificity for iron deficiency anemia and iron deficiency in adults (ie, anemia need not always be present). Blue sclera has been reported, albeit infrequently, in other conditions such as rheumatoid arthritis, myasthenia gravis, and long-term steroid therapy.